PCP
VTGN icon

Proficio Capital Partners’s VistaGen Therapeutics VTGN Stock Holding History

Proficio Capital Partners’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3
Closed – – 1777
2018
Q4 		$0 Hold
3
– – ﹤0.01% 1283
2018
Q3 		$0 Hold
3
– – ﹤0.01% 1309
2018
Q2 		$0 Hold
3
– – ﹤0.01% 1344
2018
Q1 		$0 Hold
3
– – ﹤0.01% 1346
2017
Q4 		$0 Hold
3
– – ﹤0.01% 1323
2017
Q3 		$0 Hold
3
– – ﹤0.01% 1331
2017
Q2 		$0 Buy
+3
New +$176 ﹤0.01% 1334

Other funds holding VTGN

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Proficio Capital Partners's VTGN Position: Q1 2019 in Review

Proficio Capital Partners sold out of VistaGen Therapeutics (VTGN) in Q1 2019, closing a stake of 3 shares.

Proficio Capital Partners first reported a position in VTGN in Q2 2017 and held it in 7 quarters. The position peaked at $0 in Q4 2018. 25 funds tracked by Wall St. Rank hold VTGN as of Q1 2019.

  • Proficio Capital Partners reported no remaining VistaGen Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 3 VistaGen Therapeutics shares in Q1 2019.
  • Proficio Capital Partners first reported a position in VistaGen Therapeutics in Q2 2017 and held it in 7 quarters.
  • Proficio Capital Partners's VistaGen Therapeutics position peaked at $0 in Q4 2018.
  • 25 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2019.

Based on Proficio Capital Partners's 13F filing for Q1 2019, filed 13 May 2019.